CIDP: Managing Chronic Inflammatory Demyelinating Polyneuropathy with IVIG
CIDP is a slow-building autoimmune nerve condition that, left untreated, can cause lasting weakness. IVIG infusion therapy is one of the most established treatments available.
What is CIDP?
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune condition in which the immune system attacks the protective myelin coating around peripheral nerves, disrupting how well those nerves can send signals. Unlike Guillain-Barre syndrome, which comes on suddenly, CIDP develops gradually over at least two months and tends to be a longer-term, relapsing condition.
Common symptoms include progressive weakness and numbness in the arms and legs, loss of reflexes, and difficulty with balance or fine motor tasks like buttoning a shirt.
How infusion therapy helps
Intravenous immunoglobulin (IVIG) is one of the first-line treatments for CIDP. It works by modulating the immune system's activity, helping to calm the attack on the nerves' myelin coating, and is often effective at both improving symptoms and preventing further nerve damage.
Because CIDP tends to relapse, many patients need IVIG on an ongoing maintenance schedule, typically every few weeks, with the exact interval adjusted based on how symptoms respond over time.
Diagnosed with CIDP?
Our physician-led team coordinates ongoing IVIG therapy with your neurologist to help protect nerve function.
Call (551) 336-5580This article is for general educational purposes and is not a substitute for medical advice. Treatment decisions should always be made with your physician based on your individual diagnosis and health history.